🔴 Neurosense Therapeutics is trading 5.1% down today as crude oil and Treasury yields pressured valuations

Neurosense Therapeutics is trading 5.1% down at $6.82, primarily amid broader risk-off conditions.

• On September 23, 2026, biotechnology stocks gained 2.07%, while the Nasdaq Composite fell 1.00%; rising crude oil and Treasury yields pressured equity valuations.
• No new company-specific announcement was identified; the latest communication remained its September 10 H.C. Wainwright conference notice, updated September 22.
• The reverse split remains a recent trading-dynamics factor, but was not a new catalyst today.